

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human Osteoactivin/GPNMB in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant mouse Osteoactivin is observed.
<b>Source</b>	Monoclonal Mouse IgG <sub>2B</sub> Clone # 303822
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human Osteoactivin/GPNMB isoform 2 Ala22-Asn486 Accession # NP_002501
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Western Blot</b>	1 µg/mL	Recombinant Human Osteoactivin/GPNMB Fc Chimera (Catalog # 2550-AC) under non-reducing conditions only
<b>Immunocytochemistry</b>	8-25 µg/mL	Immersion fixed MG-63 human osteosarcoma cell line
<b>Intracellular Staining by Flow Cytometry</b>	0.25 µg/10 <sup>6</sup> cells	See Below
<b>CyTOF-ready</b>	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

Osteoactivin (also GPNMB and DC-HIL) is a variably glycosylated 75-125 kDa member of the NMB/pMEL-17 family of molecules. It is found in multiple subcellular sites, but is most often associated with the endosomal/lysosomal compartment (1-3). Human Osteoactivin is a 560 amino acid (aa) type I transmembrane protein. Its precursor contains a 21 aa signal sequence, a 465 aa luminal/extracellular domain, a 21 aa transmembrane segment and a 53 aa cytoplasmic tail (4, 5). The luminal region contains an N-terminal heparin-binding motif (aa 23-26), multiple glycosylation sites, an RGD motif (aa 64-66) and an 88 aa PKD domain (aa 240-327). The intracellular tail has an ITAM (Y-x-x-l) and lysosomal targeting (L-L) motif (4, 5). The extracellular/luminal region shares 74% and 77% aa identity with the equivalent regions in mouse and canine, respectively. Multiple isoforms would appear to exist. There is one alternate splice form known that shows a 12 aa insert between aa 339-340 (6). An additional 206 aa isoform shows a mutation at position # 181 that results in a 26 aa substitution for the C-terminal 380 amino acids (7, 8). This has the potential to be soluble and may represent a counterpart to a secreted isoform of rat Osteoactivin (9). Cells known to express Osteoactivin include macrophages/Kupffer cells, fibroblasts, osteoblasts, myeloid dendritic cells, retinal pigment epithelial cells and melanocytes, plus fetal chondrocytes and stratum basale keratinocytes (3-5, 10-12). In mice, Osteoactivin is reported to bind to heparan sulfate-proteoglycan, possibly on the surface of endothelial cells and may also interact with integrins (13). It also appears to act as an inflammatory suppressor gene, as its expression downregulates the macrophage inflammatory response by inhibiting IL-6 and IL-12 p40 production (3).

**References:**

1. Bachner, D. *et al.* (2002) *Gene Exp. Patterns* **1**:159.
2. Safadi, F.F. *et al.* (2002) *J. Cell. Biochem.* **84**:12.
3. Ripoll, V.M. *et al.* (2007) *J. Immunol.* **178**:6557.
4. Owen, T.A. *et al.* (2003) *Crit. Rev. Eukaryot. Gene Expr.* **13**:205.
5. Weterman, M.A.J. *et al.* (1995) *Int. J. Cancer* **60**:73.
6. Kuan, C-T. *et al.* (2006) *Clin. Cancer Res.* **12**:1970.
7. Lennerz, V. *et al.* (2005) *Proc. Natl. Acad. Sci. USA* **102**:16013.
8. Genbank Accession # AAH11595.
9. Abdelmagid, S.M. *et al.* (2007) *J. Cell. Physiol.* **210**:26.
10. Haralanova-Ilieva, B. *et al.* (2005) *J. Hepatol.* **42**:565.
11. Ahn, J.H. *et al.* (2002) *Blood* **100**:1742.
12. Anderson, M.G. *et al.* (2002) *Nat. Genet.* **30**:81.
13. Shikano, S. *et al.* (2001) *J. Biol. Chem.* **276**:8125.